Across TCGA pan-cancer cohorts, ATP6AP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP6AP1 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATP6AP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6AP1 expression acts as an unfavorable survival marker.
UCEC, SKCM, and LUSC are the cancer types where ATP6AP1 Mutation most reproducibly stratifies survival.